Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells

被引：0
|
作者：
Park, Ye-Lim
Kim, Hwang-Phill
Cheon, Seul-Ki
Kang, Jun-Kyu
Lim, Yoojoo
Song, Sang-Hyun
Han, Sae-Won
Kim, Tae-you
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5214
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Vasan, N.
    Razavi, P.
    Johnson, J. L.
    Shao, H.
    Reznik, E.
    Smith, M. L.
    Sebra, R.
    Cantley, L. C.
    Scaltriti, M.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 1 - 1
  • [22] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Liu, Songlin
    Tang, Yunhong
    Yan, Maomao
    Jiang, Weixi
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 763 - 772
  • [23] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Songlin Liu
    Yunhong Tang
    Maomao Yan
    Weixi Jiang
    Investigational New Drugs, 2018, 36 : 763 - 772
  • [24] Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors
    Janku, F.
    Tsimberidou, A. M.
    Garrido-Laguna, I.
    Hong, D. S.
    Naing, A. M.
    Falchook, G. S.
    Fu, S.
    Luthra, R.
    Wang, X.
    Kurzrock, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 83
  • [25] Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
    Vincent, Loic
    Thomas, Anne
    Ma, Jianguo
    Clark, Anderson
    Shaw, Jamie
    Guerif, Stephane
    Egile, Coumaran
    Lager, Joanne
    Debussche, Laurent
    Lengauer, Christoph
    Garcia-Echeverria, Carlos
    Ogden, Janet A.
    CANCER RESEARCH, 2011, 71
  • [26] CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    Vora, Sadhna R.
    Juric, Dejan
    Kim, Nayoon
    Mino-Kenudson, Mari
    Huynh, Tiffany
    Costa, Carlotta
    Lockerman, Elizabeth L.
    Pollack, Sarah F.
    Liu, Manway
    Li, Xiaoyan
    Lehar, Joseph
    Wiesmann, Marion
    Wartmann, Markus
    Chen, Yan
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kim, Sunkyu
    Schlegel, Robert
    Huang, Alan
    Engelman, Jeffrey A.
    CANCER CELL, 2014, 26 (01) : 136 - 149
  • [27] Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer
    Chowdhury, Saikat
    Ahmed, Jibran
    Haridas, Valsala
    Hong, David S.
    Kopetz, Scott
    Shen, John Paul
    CANCER RESEARCH, 2024, 84 (06)
  • [28] PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku, F.
    Tsimberidou, A. M.
    Garrido-Laguna, I.
    Hong, D. S.
    Naing, A.
    Falchook, G. S.
    Wheler, J. J.
    Fu, S.
    Piha-Paul, S. A.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] PIK3CA and PIK3R1 mutations in cancer: from the mechanism of activation to PI3K targeted therapies
    Rzepecka, Iwona K.
    Tysarowski, Andrzej
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [30] The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
    Roper, Jatin
    Richardson, Michael P.
    Wang, Wei Vivian
    Richard, Larissa Georgeon
    Chen, Wei
    Coffee, Erin M.
    Sinnamon, Mark J.
    Lee, Lydia
    Chen, Peng-Chieh
    Bronson, Roderick T.
    Martin, Eric S.
    Hung, Kenneth E.
    PLOS ONE, 2011, 6 (09):
12345